Gilead Sciences entered a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP).  This is a key component of Gilead’s larger coordinated efforts, now bringing together the resources and expertise of PEPFAR and the Global Fund, to further advance access to lenacapavir for PrEP for up to t...